KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income: 2009-2025

Historic Interest & Investment Income for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $125.7 million.

  • Vertex Pharmaceuticals' Interest & Investment Income fell 4.92% to $125.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $497.2 million, marking a year-over-year decrease of 23.44%. This contributed to the annual value of $598.1 million for FY2024, which is 2.70% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Interest & Investment Income stood at $125.7 million for Q3 2025, which was up 2.70% from $122.4 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Interest & Investment Income peaked at $181.2 million during Q1 2024, and registered a low of $1.1 million during Q2 2021.
  • For the 3-year period, Vertex Pharmaceuticals' Interest & Investment Income averaged around $143.8 million, with its median value being $132.2 million (2024).
  • In the last 5 years, Vertex Pharmaceuticals' Interest & Investment Income plummeted by 88.07% in 2021 and then surged by 7,562.50% in 2023.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Interest & Investment Income stood at $1.2 million in 2021, then soared by 7,066.67% to $86.0 million in 2022, then soared by 108.72% to $179.5 million in 2023, then fell by 28.58% to $128.2 million in 2024, then decreased by 4.92% to $125.7 million in 2025.
  • Its last three reported values are $125.7 million in Q3 2025, $122.4 million for Q2 2025, and $120.9 million during Q1 2025.